Small renal masses: A positive surgical margin does not affect survival
The incidence and consequences of positive surgical margins after partial nephrectomy are important issues in the management of localized renal cell carcinoma. A recent population-based study demonstrates a slightly higher rate of positive margins...04/24/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 24, 2013 Category: Cancer & Oncology Source Type: news
Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis
Renal cell carcinoma (RCC) may involve both kidneys. When bilateral nephrectomy is necessary renal replacement therapy is mandatory. Treating such patients with sequential therapy based on cytokines, antiangiogenic factors and mammalian target of rapamycin (mTOR) inhibitors is challenging.04/13/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 13, 2013 Category: Cancer & Oncology Source Type: news
Kidney sparing surgery underutilized for patients who need it most
The study found that partial and complete kidney removal (total nephrectomy) and energy-based techniques to destroy tumors are all on the rise. Surprisingly, the patients most in need of kidney-sparing surgery are still more likely to undergo total nephrectomy.04/06/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 6, 2013 Category: Urology & Nephrology Source Type: news
Many Patients With Kidney Insufficiency Undergo Complete Kidney Removal When Kidney-Sparing Surgery May Be Indicated
Researchers at the University of California, San Diego School of Medicine have released study results that show national treatment trends in the surgical management of patients with kidney disease. The study found that partial and complete kidney removal (total nephrectomy) and energy-based techniques to destroy tumors are all on the rise. Surprisingly, the patients most in need of kidney-sparing surgery are still more likely to undergo total nephrectomy. The findings recently published online in BJU International... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 27, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news
Kidney sparing surgery underutilized for patients who need it most
(University of California - San Diego) Researchers at the University of California, San Diego School of Medicine have released study results that show national treatment trends in the surgical management of patients with kidney disease. The study found that partial and complete kidney removal (total nephrectomy) and energy-based techniques to destroy tumors are all on the rise. Surprisingly, the patients most in need of kidney-sparing surgery are still more likely to undergo total nephrectomy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 25, 2013 Category: Global & Universal Source Type: news
Does Timing of Cytoreductive Nephrectomy Impact Patient Survival With Metastatic Renal Cell Carcinoma?
OBJECTIVE: To compare outcomes of metastatic renal cell carcinoma (mRCC) patients who underwent primary cytoreductive nephrectomy (CRN), followed by adjuvant sunitinib therapy, vs those who underwent primary sunitinib therapy before planned CRN.02/19/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 19, 2013 Category: Cancer & Oncology Source Type: news
Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study
Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study
AGS-003, first fully personalized, dendritic-based immunotherapy
being evaluated in combination with targeted therapy for mRCC
Visit ADAPTkidneycancer.com & Follow on Twitter @ADAPTkdnycancer
DURHAM, N.C. – January 15, 2012 – Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced that the first patients have been enr...
Source: Kidney Cancer Association - January 23, 2013 Category: Urology & Nephrology Source Type: news
Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study
Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT StudyAGS-003, first fully personalized, dendritic-based immunotherapy being evaluated in combination with targeted therapy for mRCCVisitADAPTkidneycancer.com& Follow on Twitter@ADAPTkdnycancerDURHAM, N.C.– January 15, 2012– Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced that the first patients have been enrolled in the ADAPT P...
Source: Kidney Cancer Association - January 23, 2013 Category: Urology & Nephrology Source Type: news
Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study
Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study
AGS-003, first fully personalized, dendritic-based immunotherapy
being evaluated in combination with targeted therapy for mRCC
Visit ADAPTkidneycancer.com & Follow on Twitter @ADAPTkdnycancer
DURHAM, N.C. – January 15, 2012 – Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced that the first patients hav...
Source: Kidney Cancer Association - January 23, 2013 Category: Cancer & Oncology Source Type: news
